36
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prevention and control of non-communicable diseases in the COVID-19 response

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Moving towards universal health coverage, promoting health and wellbeing, and protecting against health emergencies are the WHO global priorities 1 that are shared by the proposed WHO European Programme of Work 2020–25. 2 The coronavirus disease 2019 (COVID-19) pandemic has underlined the importance of interconnecting these strategic priorities. Of the six WHO regions, the European region is the most affected by non-communicable disease (NCD)-related morbidity and mortality 3 and the growth of the NCDs is concerning. Cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes are among the leading causes of death and disability in the region, 3 and an increasing proportion of children and adults are living with overweight or obesity, 4 one of the major risk factors for NCDs. Prevention and control of NCDs are important during this pandemic because NCDs are major risk factors for patients with COVID-19. 5 Additionally, some of the restrictive measures such as lockdowns, social distancing, and travel restrictions to reduce the spread of infection in many countries impact specifically on people living with NCDs by limiting their activity, ability to secure healthy foods, and access to preventive or health promotion services. 6 The COVID-19 pandemic has had widespread health impacts, revealing the particular vulnerability of those with underlying conditions. In Italy, a recent report revealed that the majority (96·2%) of patients who have died in-hospital from COVID-19 had comorbidities, primarily NCDs; the most prevalent NCDs among these patients were hypertension (69·2%), type 2 diabetes (31·8%), ischaemic heart disease (28·2%), chronic obstructive pulmonary disease (16·9%), and cancer (16·3%). 7 An association between COVID-19 severity and NCDs has also been reported in Spain, 8 China, 9 and the USA. 10 However, many COVID-19 deaths also occur in older people who often have existing comorbidities. 11 Body-mass index (BMI) might also be associated with the severity of COVID-19; in China, patients with severe COVID-19 and non-survivors typically had a high BMI (>25 kg/m2). 12 The impact of COVID-19 response measures on NCDs is multifaceted. Physical distancing or quarantine can lead to poor management of NCD behavioural risk factors, including unhealthy diet, physical inactivity, tobacco use, and harmful use of alcohol. 13 Evidence from this and previous pandemics suggests that without proper management, chronic conditions can worsen due to stressful situations resulting from restrictions, insecure economic situations, and changes in normal health behaviours. As with other health service and preventive programmes, the postponement of routine medical appointments and tests can delay NCD management, while physical distancing, restricted access to primary health care units, pharmacies, and community services, alongside a reduction of transport links, all disrupt continuity of care for NCD patients. This disruption of routine health services and medical supplies risks increasing morbidity, disability, and avoidable mortality over time in NCD patients. Additionally, patients with severe obesity who require intensive care have increased patient management needs. 6 The prevention and control of NCDs have a crucial role in the COVID-19 response and an adaptive response is required to account for the needs of people with NCDs. Prevention of NCDs is important since the true scale of at-risk groups is probably underestimated, given that many cases of hypertension and diabetes are undiagnosed.14, 15 Communities and health systems need to be adaptive to both support and manage the increased risks of people with known NCDs and exercise sensitivity about the vulnerability of the large population with undiagnosed NCDs and those at increased risk of NCDs. The COVID-19 response and continued and strengthened focus on NCD prevention and management are key and interlinked aspects of public health at the present time. If the COVID-19 response is not adapted to encompass prevention and management of NCD risks, we will fail many people at a time when their vulnerability is heightened. What steps should be taken to adapt the COVID-19 response? The WHO Regional Office for Europe has started to develop a list of actions that could be adapted by countries to address the needs of those at risk of NCDs or who are already living with NCDs, together with practical considerations for teams developing COVID-19 response plans at local or national levels (table ). Table Responses and risks related to NCD prevention and control during the COVID-19 pandemic NCD-specific responses Associated risks Community transmission with containment measures such as physical distancing and public service and institution closures or restrictions Lengthened time spent indoors Use technology to provide knowledge and support for management of NCDs, online information on exercise and mental health self-management classes, healthy recipes for home preparation, and online delivery of healthy foods, among other responses Reduced physical activity and increased strain on mental health might result in greater consumption of unhealthy foods and harmful use of tobacco and alcohol Family members at home Provide special arrangements for families with NCD patients to self-isolate Risk of increased contact with younger family members at home Inadequate access to medicines Use telemedicine more, allow local or community doctors and pharmacists to renew or extend drug prescriptions, deliver essential NCD drugs to home Shortage of essential medicines such as insulin and other NCD-specific medications Transport and other services restricted Prioritise and ensure continued community level services in a safe way to cater for NCD patients' needs Restricted transport facilities and family support for continued NCD care Infection control Early detection and laboratory testing Prioritise NCD patients for COVID-19 testing; triaging should take account of whether patients have NCDs and are immunocompromised Those NCD patients for whom visits to health facilities are essential could be at greater risk of getting exposed to COVID-19 Contact tracing Focus especially on those with increased risk factors for NCDs and NCD patients (ie, patients living with obesity) and alert and follow up closely any possible contacts for NCD patients NCD patients might be unaware of the additional risks posed on them Extensive testing Prioritise NCD patients for testing when possible and promote the need for testing NCD patients might be less motivated or able to actively seek testing (in a safe, physically distanced manner) Health-care settings (infection control) Provide NCD patients and health-care staff working in NCD services with special training and personal protective equipment, as well as health-care professionals at increased risk of NCDs NCD patients with comorbidities are at increased risk of infection; health-care staff working in NCD clinics are therefore also at increased risk of infection NCD=non-communicable disease. COVID-19=coronavirus disease 2019. Patients living with obesity and NCDs are at increased risk of the health impacts of emergencies such as COVID-19. 16 NCD health-care staff and associated workers and volunteers should be centrally involved in the planning of COVID-19 response strategies to ensure that the needs of patients and caregivers are addressed. Specific advice should be made available nationally and locally for patients living with NCDs, their families, and their caregivers. Prevention and control of obesity and NCDs are crucial in preparedness for this and future public health threats. A streamlined response to COVID-19 in the context of NCDs is important to optimise public health outcomes and reduce the impacts of this pandemic on individuals, vulnerable groups, key workers, and society.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found

          Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

          There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            2018 ESC/ESH Guidelines for the management of arterial hypertension

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

              Currently, the number of patients with coronavirus disease 2019 (COVID-19) has increased rapidly, but relationship between comorbidity and patients with COVID-19 still not clear. The aim was to explore whether the presence of common comorbidities increases COVID-19 patients’ risk. A literature search was performed using the electronic platforms (PubMed, Cochrane Library, Embase, and other databases) to obtain relevant research studies published up to March 1, 2020. Relevant data of research endpoints in each study were extracted and merged. All data analysis was performed using Stata12.0 software. A total of 1558 patients with COVID-19 in 6 studies were enrolled in our meta-analysis eventually. Hypertension (OR: 2.29, P<0.001), diabetes (OR: 2.47, P<0.001), chronic obstructive pulmonary disease (COPD) (OR: 5.97, P<0.001), cardiovascular disease (OR: 2.93, P<0.001), and cerebrovascular disease (OR:3.89, P=0.002)were independent risk factors associated with COVID-19 patients. The meta-analysis revealed no correlation between increased risk of COVID-19 and liver disease, malignancy, or renal disease. Hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are major risk factors for patients with COVID-19. Knowledge of these risk factors can be a resource for clinicians in the early appropriate medical management of patients with COVID-19.
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet
                Lancet
                Lancet (London, England)
                World Health Organization. Published by Elsevier Ltd.
                0140-6736
                1474-547X
                10 May 2020
                10 May 2020
                Affiliations
                [a ]WHO Regional Office for Europe, Copenhagen, Denmark
                [b ]WHO European Office for the Prevention and Control of Noncommunicable Diseases, Moscow 125009, Russia
                [c ]EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal
                [d ]Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
                [e ]National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
                Article
                S0140-6736(20)31067-9
                10.1016/S0140-6736(20)31067-9
                7211494
                32401713
                34a348b6-c682-403b-afea-c8e36beab687
                © 2020 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article